Document is current

Article History

Received: 28 September 2024

Accepted: 10 March 2025

First Online: 13 March 2025

Declarations

:

: First insights and future research perspectives from the sarcoidosis registry at the Medical University of ViennaC Guttmann-Ducke, M Lutnik, MR Gysan, P Sarova, C Milacek, C Bal, W Graninger, H Prosch, D Gompelmann and M Idzko. The authors declare following conflicts of interest: Claudia Guttmann- Ducke: Speaker Fees Boehringer Ingelheim all outside the submitted work, Marco Idzko: lecture fees from AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Menarini, MSD, Novartis, Roche, Sanofi, and Thermofischer; and advisory board fees from Alk-Pharma, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Novartis, and Sanofi, all outside the submitted work; Daniela Gompelmann: lecture and travel fees from Olympus, Pulmonx, Astra Zeneca, Boehriger Ingelheim, Erbe, Berlin Chemie, Chiesi, MSD all outside the submitted work. Martin Lutnik: no conflict of interest; Christopher Milacek: no conflict of interest; Pavla Sarova: no conflict of interest; Maximilian Robert Gysan: Fees Boehringer Ingelheim all outside the submitted work. Wolfgang Graninger: no conflict of interest. Helmut Prosch: Fees from AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme, Novartis, Roche/Intermune, Sanofi, Siemens Healthcare, and Takeda; and research support from AstraZeneca, Boehringer, Siemens, and EU4Healthall outside the submitted work. Christina Bal: Fees Olympus all outside the submitted work.